RELATIONSHIP BETWEEN RENAL FUNCTION AND BLOOD LEVEL OF CHROMOGRANIN A

REFERENCES

• Baudin D, Gigliotti A, Ducreux M, Ropers J, Comoy E, Sabourin J C, Bidart J M, Cailleux A F, Bonacci R, Ruffle P, Schlumberger M. Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 1998; 78(8)1102–1107
   PubMed Web of Science ®Google Scholar
• Degorce F, Goumon Y, Jacquemart L, Vidaud C, Bellanger L, Pons-Anicet D, Seguin P, Metz-Boutigue M B, Aunis D. A new human chromogranin A (CGA) immunoradiometric assay involving monoclonal antibodies raised against the unprocessed central domain (145–245). Br J Cancer 1999; 79(1)65–71
   PubMedGoogle Scholar
• Taupenot L, Remacle J E, Helle K B, Aunis D, Bader M F. Recombinant human chromogranin A: expression, purification and characterization of the N-terminal derived peptides. Regul Pept 1995; 7; 56(1)71–88
   PubMedGoogle Scholar
• Maack T, Hyung Park C, Camargo M JF. Renal filtration, transport and metabolism of proteins. The Kidney: Physiology and Pathophysiology, D W Seldin, G Giebisch. 2nd ed., Raven Press, New York 1992; 3005–3038
   Google Scholar
• Bianchi C, Donadio C, Tramonti G, Auner I, Lorusso P, Deleide G, Lunghi F, Vannucci C, Vitali S, Ricchiuti V, Guzzardi R. High and preferential accumulation in the kidney of anionicand cationic small proteins. Contrib Nephrol 1990; 83: 39–46
   PubMedGoogle Scholar
• Johansson B G, Ravnskov U. The serum levels and urinary excretion of a α2M, β2M and lysozyme in renal disease. Scand J Urol Nephrol 1972; 6: 249–256
   PubMed Web of Science ®Google Scholar
• Sturfelt G, Truedsson L, Thysell H, Bjork H. Serum level of complement factor D in systemic lupus erythematosus – an indicator of glomerular filtration rate. Acta Med Scand 1984; 216: 171–177
   PubMedGoogle Scholar
• Grubb A, Simonsen O, Strufelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and β2M as a measure of glomerular filtration rate. Acta Med Scand 1985; 218: 499–503
   PubMed Web of Science ®Google Scholar
• Kusano E, Suzuki M, Asano Y, Itoh Y, Takagi K, Kawai T. Human αlM and its relationship to renal function. Nephron 1985; 41: 320–324
   PubMed Web of Science ®Google Scholar
• Acchiardo S, Kraus A P, Jennings B R. β2M levels in patients with renal insufficiency. Am J Kidney Dis 1989; 13: 70–74
   PubMed Web of Science ®Google Scholar
• Kyhse-Andersen J, Schmidt C, Nordin G, Andersson B, Nilsson-Ehle P, Lindstrom V, Grubb A. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994; 40: 1921–1926
   PubMed Web of Science ®Google Scholar
• Newman D J, Thakkar H, Edwards R G, Wilkie M, White T, Grubb A O, Price C P. Serum cystatin C measured by automated immunoassay: a more sensitive marker of changes in GFR than serum creatinine. Kidney Int 1995; 47: 312–318
   PubMed Web of Science ®Google Scholar
• Schardijn G HC. Statius van Eps LW: β2M: its significance in the evaluation of renal function. Kidney Int 1987; 32: 635–641
   PubMed Web of Science ®Google Scholar
• Tramonti G, Ferdeghini M, Donadio C, Annichiarico C, Norpoth M, Bianchi R, Bianchi C. Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rate. Renal Failure 1998; 20(2)295–302
   PubMed Web of Science ®Google Scholar
• Lasson A, Borgstrom A, Ohlsson K. Elevated pancreatic sectetory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedure. Scand J Gastroenterol 1986; 21: 1275–1280
   PubMed Web of Science ®Google Scholar
• DeSanto N, Veneroso S, Capodicasa G, et al. Tumor markers in uremia: carcinoembryonic antigen, neuron-specific enolase, carbohydrate antigen CA-50 and α-fetoprotein. Am J Nephrol 1986; 6: 458–463
   PubMedGoogle Scholar
• Docci D, Pistocchi B, Turci F, et al. Serum CA 19-9 and Ca 50 antigens in hemodialysis patients. Clinical Nephrology 1987; 27: 179–181
   PubMedGoogle Scholar
• Zeferos N, Digenis G B, Christophoraki M, et al. Tumor markers in patients undergoing hemodialysis or kidney transplantation. Nephron 1991; 59: 618–620
   PubMed Web of Science ®Google Scholar
• Banfi G, Murone M, Slaviero G. High concentration of tumor-associated trypsin inhibitor in hemodialyzed patients. Clin Chem 1988; 34: 174–175
   PubMedGoogle Scholar
• Kamata K, Uchida M, Tekeuchi Y, et al. Increased serum concentrations of pro-gastrin-releasing peptide in patients with renal dysfunction. Nephrol Dial Transplant 1996; 11: 1267–1270
   PubMedGoogle Scholar
• Polenakovic M, Sikole A, Dzikova B, et al. Tumor markers in maintenance hemodialysis patients with acquired renal cystic disease. JASN 1996; 7: 1340
   Google Scholar
• Nakahama H, Tanaka Y, Fujita Y, et al. CYFRA 21-1 and Pro-GRP, tumor makers of lung cancer, are elevated in chronic renal failure patients. Respirology 1998; 3: 207–210
   PubMedGoogle Scholar
• Cases A, Filella X, Molina R, et al. Tumor markers in chronic renal failure and hemodialysis patients. Nephron 1991; 57: 183–186
   PubMed Web of Science ®Google Scholar
• Eskiocak S, Dortok H, Alvur M, et al. Tumor markers in chronic renal failure and hemodialysis patients. Nephrol Dial Transplant 1995; 10: 1256
   PubMedGoogle Scholar
• Tramonti G, Ferdeghini M, Donadio C, Norpoth M, Annichiarico C, Bianchi R, Bianchi C. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia. Cancer Detection and Prevention 2000; 24(1)86–90
   PubMedGoogle Scholar
• Bianchi C, Bonadio M, Donadio C, Tramonti G, Figus S. Measurement of glomerular filtration rate in man using DTPA-99mTc. Nephron 1979; 24: 174–178
   PubMed Web of Science ®Google Scholar
• Tramonti G, Donadio C, Ferdeghini M, Annichiarico C, Norpoth M, Bianchi R, Bianchi C. Serum tumor-associated trypsin inhibitor (TATI) and renal function. Scand J Clin Lab Invest 1996; 56: 653–656
   PubMed Web of Science ®Google Scholar
• Tramonti G, Ferdeghini M, Donadio C, Annichiarico C, Norpoth M, Bianchi R, Bianchi C. Tumor-associated trypsin inhibitor (TATI) and renal function. Kidney Int 1997; 52(suppl 63)S179–S181
   Google Scholar
• Lewin E, Nielsen P K, Olgaard K. The calcium/parathyroid hormone concept of the parathyroid glands. Curr Opin Nephrol Hypertens 1995; 4(4)324–333
   PubMedGoogle Scholar
• Bianchi C, Donadio C, Tramonti G, Vannucci C, Ricchiuti V, Casani A, Lorusso P, Bonino C, Seccamani F, Lunghi F. L'accumulation renale de α1M radioiodee augmente chez le rat mononephrectomise. Nephrologie 1992; 13: 221–225
   PubMedGoogle Scholar
• Bianchi C, Donadio C, Tramonti G, Vannucci C, Ricchiuti V, Casani A, Lucchetti A, Bonino C, Lunghi F. Increased kidney accumulation of 131I-lysozyme in the uninephrectomized rat. Contrib Nephrol 1993; 101: 85–91
   PubMedGoogle Scholar
• Bianchi C, Donadio C, Tramonti G, Vannucci C, Ricchiuti V, Casani A, Della Capanna S, Lorusso P, Bonino C, Lunghi F. Kidney accumulation of α2M increases in uninephrectomized rats. Abstract of the XIIth International Congress of Nephrology. June, 13–181993. JerusalemIsrael, 554
   Google Scholar
• Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997; 51: 2–15
   PubMed Web of Science ®Google Scholar